Aurinia Pharmaceuticals Inc. (AUPH) is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that:
(i) Aurinia was experiencing declining revenues; (ii) Aurinia’s 2022 sales outlook for the Company’s only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS’s commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you incurred a loss on AUPH stocks purchased between May 7, 2021 and February 25, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Eastern District of New York, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until June 14, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Aurinia Pharmaceuticals Inc. Class Action Lawsuit
Aurinia Pharmaceuticals Inc. Lawsuit
AUPH Class Action Lawsuit
Aurinia Pharmaceuticals Inc. (AUPH) Class Action Lawsuit